Characterization of prodigiosin pigment by Serratia marcescens and the evaluation of its bioactivities

Basit Öğe Kaydı
dc.authorid0000-0002-0290-1166
dc.authorid0000-0002-8584-1145
dc.contributor.authorKoyun, Merve Tunca
dc.contributor.authorSirin, Seda
dc.contributor.authorAslim, Belma
dc.contributor.authorTaner, Gokce
dc.contributor.authorDolanbay, Serap Nigdelioglu
dc.date.accessioned2026-02-12T21:04:53Z
dc.date.available2026-02-12T21:04:53Z
dc.date.issued2022
dc.departmentBursa Teknik Üniversitesi
dc.description.abstractThe aim of the present study is to discover a bacterial pigment providing protection and prevention of neurological damage and cancer development, which can have a role as a non-synthetic food additive in the food industry as well as an active drug ingredient of anticancer drugs and pharmaceuticals for neural injury. Within this scope, Serratia marcescens MB703 strain was used to produce prodigiosin. Characterization of the prodigiosin was carried out using UV-VIS, and FT-IR. In addition, its inhibitory action on AChE and antioxidant activities were determined. The cytotoxic, genotoxic and antigenotoxic activities of the prodigiosin as well as its anti proliferative activities were detected. It was determined that the maximum production of the prodigiosin (72 mg/L). The prodigiosin was found to cause no significant difference in its inhibitory effect on AChE. The prodigiosin was found effective on all antioxidant parameters tested. The IC50 values of the prodigiosin on SK-MEL30 and HT-29 cells were calculated as 70 and 47 mu M, respectively. This IC50 values of the prodigiosin showed no cytotoxic effect on L929 cells. Prodigiosin did not have genotoxic effect alone and also seem to decrease DNA damage induced by H2O2 in L929 cells. The findings of in vitro experimental studies suggest that using the prodigiosin pigment as a drug candidate for cancer and neurodegenerative disease therapy is both effective and safe.
dc.description.sponsorshipGazi University, Turkey [05/2018-13]
dc.description.sponsorshipThis study was supported by the Gazi University, Turkey (grant number 05/2018-13).
dc.identifier.doi10.1016/j.tiv.2022.105368
dc.identifier.issn0887-2333
dc.identifier.issn1879-3177
dc.identifier.pmid35476923
dc.identifier.scopus2-s2.0-85129111930
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.tiv.2022.105368
dc.identifier.urihttps://hdl.handle.net/20.500.12885/6711
dc.identifier.volume82
dc.identifier.wosWOS:000798069500003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofToxicology in Vitro
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260212
dc.subjectAnticancer activity
dc.subjectFT-IR
dc.subjectHT-29 human colon cancer cells
dc.subjectNeuroprotective effect
dc.subjectProdigiosin pigment
dc.subjectSerratia marcescens
dc.subjectSH-SY5Y human neuroblastoma cells
dc.subjectSK-MEL-30 human melanoma cancer
dc.subjectUV-VIS spectroscopy
dc.titleCharacterization of prodigiosin pigment by Serratia marcescens and the evaluation of its bioactivities
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu